Key positives include a highly differentiated ADC technology base, an already approved oncology product, and a pipeline that targets both hematologic and solid tumors. The company maintains strong short‑term liquidity and has structured its capital spending to be relatively light, focusing resources on clinical and scientific work. High gross margins on existing product sales show attractive unit economics once scale is achieved.

Major risks center on sustained losses, heavy cash burn, and a highly leveraged, negative‑equity balance sheet. Competitive and clinical risks are also significant: setbacks in key trials, slower‑than‑hoped uptake of ZYNLONTA, or superior competing products could undermine revenue potential. The combination of scientific, regulatory, and financial uncertainty is typical in this sector but particularly acute here given the level of existing obligations.

The forward picture is a trade‑off between scientific promise and financial strain. If ZYNLONTA expands successfully into earlier‑line settings and the exatecan‑based pipeline yields positive clinical data, ADCT could grow into its cost base and eventually improve its financial profile. If progress is slower, the company may face increasing pressure from its leverage and ongoing cash burn. Overall, the outlook is highly dependent on upcoming trial results, execution on commercialization, and continued access to supportive capital structures, rather than on current financial performance alone.